Use of the cholinesterase inhibitor rivastigmine (Exelon; Novartis) does not decrease the duration of delirium in critically ill patients in intensive care units (ICUs) when added to standard treatment with haloperidol, and might increase the risk for death, according to results of a large, placebo-controlled trial published online November 5 in The Lancet.
No Benefit, Possible Harm With Cholinesterase Inhibitor for Delirium
Комментариев нет:
Отправить комментарий